![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, May 16, 2019 2:21:47 PM
GMP Production Scientist – Cell Therapy- London / Cambridge
An excellent opportunity has arisen for a GMP Production Scientist to join an emerging contract bioservices company. As an organisation they provide innovative GMP manufacturing services and process development for novel cell and gene therapy products.
The role will initially be based at their site in London and will move to South Cambridge in the latter part of the year, as they are opening a brand new state of the art manufacturing facility there.
Reporting into the GMP Production Manager the GMP Production Scientist will be responsible for performing batch manufacturing of the company’s contract manufacturing products to support the delivery of Advanced Therapeutic Medicinal Products (ATMPs) as both Specials and as Investigational Medicinal Products.
Responsibilities:
*GMP production within sterile environments, formulation and banking of cellular therapy products. This will include cell culture and raw material support in compliance with validated standard operating procedures (SOPs) and regulatory requirements
*Perform and assist in the development of QC assays as part of product release, including use of flow cytometry, ELISA and ELISPOT assays, microscopy techniques, cell culture, SDS electrophoresis
*Preparing technical reports and other clinical and GMP required documentation.
*Support in process engineering and validation of cellular therapy products for successful technology transfer into the facilities with full GMP compliance
*Plan and undertake validation of new production equipment.
*Undertake daily GMP production housekeeping activities and administration.
*Assist in the labelling, packaging, storage and shipping of cellular therapy products.
Key requirements:
-BSc or MSc in a relevant scientific subject
-A minimum of 2 years’ experience in the aseptic manufacture of cellular therapies in a clean room environment
-Working knowledge of GMP for the manufacture of ATMPS
-Experience of cell culture techniques
-Additional experience of viral vector production, purification and gene therapy manufacture would be regarded but is not essential
https://www.pararecruit.com/jobs/gmp-production-scientist-cell-therapy-london-cambridge/
This is from LinkedIn (old news):
Advent Bioservices are a contract bioservices organisation providing GMP manufacturing services for a variety of ATMPs and related products, process development (PD) and ancillary services.
Advent’s head office is in London, we have lab facilities at the Royal Free Hospital Centre for Cell, Gene and Tissue Therapeutics and
a state-of-the-art manufacturing facility in South Cambridgeshire. Phase 1 of the new facility in Cambridgeshire, is due to be licensed and operational from Q1 2018 and includes two completed suites (185m2 i.a. each) comprising B, C and PD/QC labs, offices and storage space. The facility has infrastructure in situ and capacity for 7,566m2 additional development.
https://nl.linkedin.com/company/advent-bioservices
Recent NWBO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM
Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM
Kona Gold Beverage Significantly Reduces Debt from Multiple Holders • KGKG • Jul 31, 2024 9:00 AM
Avant Technologies Opens Equity Line with GHS Investments as Company Explores Expansion into Additional Technologies • AVAI • Jul 30, 2024 8:00 AM
ELEMENT79 GOLD CORP PROVIDES UPDATE ON CHACHAS COMMUNITY CHARTER AND REVENUE GENERATION, M&A ACTIVITIES • ELMGF • Jul 30, 2024 8:00 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM